Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.

Proc Natl Acad Sci U S A

Protein Studies Program, Oklahoma Medical Research Foundation, and Department of Biochemistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Published: February 2000

The cDNAs of two new human membrane-associated aspartic proteases, memapsin 1 and memapsin 2, have been cloned and sequenced. The deduced amino acid sequences show that each contains the typical pre, pro, and aspartic protease regions, but each also has a C-terminal extension of over 80 residues, which includes a single transmembrane domain and a C-terminal cytosolic domain. Memapsin 2 mRNA is abundant in human brain. The protease domain of memapsin 2 cDNA was expressed in Escherichia coli and was purified. Recombinant memapsin 2 specifically hydrolyzed peptides derived from the beta-secretase site of both the wild-type and Swedish mutant beta-amyloid precursor protein (APP) with over 60-fold increase of catalytic efficiency for the latter. Expression of APP and memapsin 2 in HeLa cells showed that memapsin 2 cleaved the beta-secretase site of APP intracellularly. These and other results suggest that memapsin 2 fits all of the criteria of beta-secretase, which catalyzes the rate-limiting step of the in vivo production of the beta-amyloid (Abeta) peptide leading to the progression of Alzheimer's disease. Recombinant memapsin 2 also cleaved a peptide derived from the processing site of presenilin 1, albeit with poor kinetic efficiency. Alignment of cleavage site sequences of peptides indicates that the specificity of memapsin 2 resides mainly at the S(1)' subsite, which prefers small side chains such as Ala, Ser, and Asp.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC26455PMC
http://dx.doi.org/10.1073/pnas.97.4.1456DOI Listing

Publication Analysis

Top Keywords

beta-secretase site
12
memapsin
11
aspartic protease
8
beta-amyloid precursor
8
precursor protein
8
domain memapsin
8
recombinant memapsin
8
memapsin cleaved
8
site
5
human aspartic
4

Similar Publications

Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's-related phenotypes.

Alzheimers Dement

January 2025

Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, The First Affiliated Hospital and Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Introduction: Interferon-induced transmembrane protein 3 (IFITM3) modulates γ-secretase in Alzheimer's Disease (AD). Although IFITM3 knockout reduces amyloid β protein (Aβ) production, its cell-specific effect on AD remains unclear.

Methods: Single nucleus RNA sequencing (snRNA-seq) was used to assess IFITM3 expression.

View Article and Find Full Text PDF

BACE-1 and ADAM-10 as Potential Peripheral Biomarkers for Alzheimer's Disease.

Curr Pharm Des

January 2025

Department of Translational Medicine and for Romagna, University of Ferrara, Via Luigi Borsari 46, 44121, Ferrara, Italy.

Amyloid beta (Aβ) dyshomeostasis is considered the main biological aberration in Alzheimer's Disease (AD) pathology. The interplay between Aβ formation and clearance is predominantly modulated by a disintegrin and a metalloproteinase 10 (ADAM10, α-secretase) and β-site APP Cleaving Enzyme 1 (BACE1), the two pivotal enzymes in both non-amyloidogenic/amyloidogenic and amyloidolytic pathways. Emerging evidence suggests that aberrations in ADAM10 and BACE1 expression, activity, and function in the brain of AD patients also manifest in peripheral fluids, suggesting their potential as blood-based biomarkers for AD diagnosis.

View Article and Find Full Text PDF

APP lysine 612 lactylation ameliorates amyloid pathology and memory decline in Alzheimer's disease.

J Clin Invest

January 2025

Growth, Development, and Mental Health of Children and Adolescence Center, Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.

Article Synopsis
  • Posttranslational modification (PTM) of the amyloid precursor protein (APP), particularly lactylation, is linked to the development of Alzheimer's disease (AD), but its specific role is still unclear.
  • Research showed reduced APP lactylation in AD patients and models, identifying lysine 612 as a key lactylation site, which affects APP processing and Aβ generation.
  • A lactyl-mimicking mutant enhanced APP trafficking and reduced cognitive decline by modifying APP interactions, suggesting that targeting APP lactylation may offer new therapeutic avenues for Alzheimer's disease.
View Article and Find Full Text PDF

Chemotherapy remains a major therapeutic approach to cancer treatment. However, its effectiveness can be compromised by the heterogeneity of a solid tumor, in which different cancer cell populations display varied responses to chemotherapy. Such an intratumor heterogeneous structure is maintained by the cancer stem-like cells (CSCs) with inherent capacities for self-renewal and differentiation, giving rise to diverse cell populations.

View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a serious neurodegenerative disorder marked by amyloid-beta plaques and neurofibrillary tangles, and it's primarily initiated by the action of the enzyme BACE1 on amyloid precursor protein (APP).
  • Researchers have discovered a small molecule that appears to effectively inhibit BACE1 by fitting well into its active site, outperforming the known drug Umibecestat (CNP-520) in terms of binding orientation and blocking the enzyme's activity.
  • The study utilized advanced techniques like virtual high-throughput screening and molecular dynamics simulations to identify and analyze potential drug leads for AD treatment, ultimately suggesting a promising new inhibitor for further development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!